New Blood Thinner Could Cut Clot Risk After Knee Surgery

New Blood Thinner Could Cut Clot Risk After Knee Surgery

Everyone who has had knee surgery knows how dangerous post-operative blood clotting may be. Even following their treatment, most individuals were urged to maintain a regular blood thinning tablet.

This situation has led many cases to critical also and there had been a great need for an option that can help control the blood clotting risk.

New Blood Thinner Could Cut Clot Risk After Knee Surgery

Therefore some of the researchers have got a new blood thinner that is believed as more effective in keeping the blood thin and save the same from clotting as well as creating other health disorders that follow blood clotting.

However, recent research reveals that a one-time shot of the investigational blood thin abelacimab could dramatically lower the risk of such clots in knee replacements individuals healing from surgery

New Blood Thinner Could Cut Clot Risk After Knee Surgery

For 412 individuals having knee replacements, the scientists compared abelacimab to enoxaparin a prescribed blood thinner.

A single dose of abelacimab decreased the chance of blood clotting by 80percent for up to a month following operation when contrasted to enoxaparin, and did not raise the chance of hemorrhage, which is a frequent adverse effect of blood thinners.

“Anti-clotting treatment with enoxaparin or other anticoagulant drugs that require daily administration is regularly given to patients who have knee replacements,” stated Jeffrey Weitz, leader of the research team. He is a hematologist at McMaster University in Hamilton, Canada, and a professor of medicine, biochemistry, and biomedical sciences. He’s also the executive director of the Thrombosis and Atherosclerosis Research Institute at the institution.

“We have discovered considerably superior protection against clots in the veins of the leg with a single injection of abelacimab after surgery compared to enoxaparin, one of the current standards of care,” Weitz said in a McMaster news release.

Anthos Therapeutics, a Massachusetts-based company that is producing abelacimab, financed the research. The study is reported in the New England Journal of Medicine on July 19 and delivered at the International Society on Thrombosis and Haemostasis’ annual meeting.

As per the researchers, abelacimab is an antibody that attaches both to the inactive and active versions of a coagulation component termed factor XI, preventing it from activating and causing blood clotting.

According to one specialist who was not involved in the trial, the medication has some potential.

“In lower-extremity orthopaedic surgery, DVT development is a major concern. This medicine could be used for fracture treatment as well as complete joint replacement. I’m looking forward to doing more study “Dr. Jeffrey Schildhorn, an orthopaedic surgeon at New York City’s Lenox Hill Hospital, agreed.

“The treatment’s ease of use is also a big bonus, according to Schildhorn. Patients only need the one-time injection, and because they won’t have to remember to take a daily blood thinner tablet, compliance should improve”, he noted.

There are unsolved issues, according to Schildhorn. What about if abelacimab is administered and there are a few incidences of hemorrhage?

“Is it possible to reverse the effects of this medicine if some people have excessive bleeding? What drugs are used to reverse anticoagulant effects [that could cause bleeding], and how long does it take for the effects to fade? “He was perplexed. Only more research, according to Schildhorn, will be able to answer those issues.

The study group feels that the favorable results of their experiment show that abelacimab could be used to treat additional heart disease.

For example, the medicine could be used “to prevent stroke in individuals with atrial fibrillation and to treat deep-vein thrombosis and pulmonary embolism clots in the leg veins and clots in the lung,” as well as in cancer patients, according to Weitz.


Please enter your comment!
Please enter your name here